Follwing the death of the firm's Founder, David E Kohne, the firm ceased operations. Jaden BioScience Inc. (Jaden) had specialized in developing and commercializing novel ultrasensitive in vitro research diagnostic assays for the scientific and medical communities. Jaden's core technology was ultrasensitive chemiluminescent signal generation and detection systems capable of detecting 5 enzyme molecules in 5 microliters. These technology platforms can be applied to detect either protein or nucleic acid analytes. The firm's assays target PCR level sensitivity without signal-amplification or the use of costly equipment and highly trained laboratory technicians. Jaden's detection technology had been adapted into simple to use assay formats using either 96 well microtiter plates or test tubes. Jaden's assays are performed in less than one hour. Jaden's first commercial research products are focused on the detection of cells and rare proteins. The company's technology ihad been designed to facilitate the identification of biomarkers and diagnostic markers that can be used to enable scientific discoveries, and in the development of pharmaceutical drugs and ultimately, individual patient management. Jaden developed ultrasensitive diagnostic platforms that are targeting PCR level sensitivity. This technology can be applied to proteins or nucleic acid analyte detection. Jaden is currently focusing on cell surface protein detection. Unlike flow cytometry methods, Jaden's platform does not require expensive equipment, doe not require a large sample size (1000 cells are sufficient), does not require highly trained technicians and can be run in resource limited laboratories.
